Abstract

Translation and transcription are frequently dysregulated in cancer. These two processes are generally regulated by distinct sets of factors. The CBFB gene, which encodes a transcription factor, has recently emerged as a highly mutated driver in a variety of human cancers including breast cancer. Here we report a noncanonical role of CBFB in translation regulation. RNA immunoprecipitation followed by deep sequencing (RIP-seq) reveals that cytoplasmic CBFB binds to hundreds of transcripts and regulates their translation. CBFB binds to mRNAs via hnRNPK and enhances translation through eIF4B, a general translation initiation factor. Interestingly, the RUNX1 mRNA, which encodes the transcriptional partner of CBFB, is bound and translationally regulated by CBFB. Furthermore, nuclear CBFB/RUNX1 complex transcriptionally represses the oncogenic NOTCH signaling pathway in breast cancer. Thus, our data reveal an unexpected function of CBFB in translation regulation and propose that breast cancer cells evade translation and transcription surveillance simultaneously through downregulating CBFB.

CBFB is highly mutated in breast cancers and is known to interact with RUNX proteins to regulate transcription. Here, the authors describe a non-canonical role of CBFB in translation regulation in which it binds to mRNAs through hnRNPK, facilitating translation by eIF4B.

Details

Title
The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription
Author
Malik Navdeep 1 ; Hualong, Yan 1 ; Moshkovich Nellie 2 ; Palangat Murali 3 ; Yang, Howard 4 ; Sanchez, Vanesa 5 ; Cai Zhuo 1 ; Peat, Tyler J 6 ; Jiang Shunlin 1 ; Liu, Chengyu 7 ; Maxwell, Lee 4 ; Mock, Beverly A 6   VIAFID ORCID Logo  ; Yuspa, Stuart H 5 ; Larson, Daniel 3   VIAFID ORCID Logo  ; Wakefield, Lalage M 2 ; Huang, Jing 1   VIAFID ORCID Logo 

 Center for Cancer Research, National Cancer Institute, National Institutes of Health, Cancer and Stem Cell Epigenetics Section, Laboratory of Cancer Biology and Genetics, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129) 
 Center for Cancer Research, National Cancer Institute, National Institutes of Health, Cancer Biology of TGF-beta Section, Laboratory of Cancer Biology and Genetics, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129) 
 National Cancer Institute, National Institutes of Health, Laboratory of Receptor Biology & Gene Expression, Center for Cancer Research, Bethesda, USA (GRID:grid.48336.3a) (ISNI:0000 0004 1936 8075) 
 Center for Cancer Research, National Cancer Institute, National Institutes of Health, High-Dimension Data Analysis Group, Laboratory of Cancer Biology and Genetics, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129) 
 Center for Cancer Research, National Cancer Institute, National Institutes of Health, In Vitro Pathogenesis Section, Laboratory of Cancer Biology and Genetics, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129) 
 Center for Cancer Research, National Cancer Institute, National Institutes of Health, Cancer Genetics Section, Laboratory of Cancer Biology and Genetics, Bethesda, USA (GRID:grid.417768.b) (ISNI:0000 0004 0483 9129) 
 Lung, and Blood Institute, National Institutes of Health, Transgenic Core, National Heart, Bethesda, USA (GRID:grid.94365.3d) (ISNI:0000 0001 2297 5165) 
Publication year
2019
Publication date
2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2220751622
Copyright
© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.